https://www.selleckchem.com/products/pki587.html
(4) Conclusions The decrease in CA II activity in epileptic patients after antiseizure treatment suggests the involvement of CA II in the pathogenesis of epilepsy. We assessed the efficacy of colchicine in COVID-19 patients through a systematic review. Six databases were searched until March 2022 for studies assessing colchicine versus control in hospitalized patients with COVID-19. The primary outcome was mortality, and secondary outcome was length of hospitalization. Inverse variance and random effect meta-analyses were performed. The
Like
Comment
Share
